Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data

Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Angelo Ruggiero, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence: Fabrizio Martora, Section of Dermatology - Depart...

Full description

Bibliographic Details
Main Authors: Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M
Format: Article
Language:English
Published: Dove Medical Press 2023-09-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
hidradenitis suppurativa
anti-il23
guselkumab
tildrakizumab
risankizumab
real life evidence
Online Access:https://www.dovepress.com/guselkumab-risankizumab-and-tildrakizumab-in-the-management-of-hidrade-peer-reviewed-fulltext-article-CCID

Internet

https://www.dovepress.com/guselkumab-risankizumab-and-tildrakizumab-in-the-management-of-hidrade-peer-reviewed-fulltext-article-CCID

Similar Items